$CSDX " CS Group is advancing discussions with healthcare providers, facilities management companies, and distribution partners that cover North America, Europe, the Middle East, Africa, and Asia/Pacific to accelerate market entry and bring MEDUSA to global audiences.
The surface disinfectant market is expected to grow from USD 5.46 Billion in 2023 to USD 8.84 Billion by 2030 driven by heightened awareness of infection prevention. CS Group's strategic valuation estimates MEDUSA can capture up to 3% market share by 2030 through focused B2B and retail channel expansion.
Thomas Fahrhöfer, President of the Board at CS Diagnostics Corp. mentioned:
"Where competitors sell volume through frequent reapplication, we deliver efficiency through lasting protection. This translates to real cost savings for facility managers and a superior value proposition in the market "
Mohammad EsSayed, Vice President of the Board at CS Diagnostics Corp., commented:
"MEDUSA requires reduced application frequency in high-traffic environments delivering cost and labour savings. With regulatory approvals progressing and a clear path to commercialization, we are confident that MEDUSA can capture meaningful market share while delivering value to our partners and end-users."
AI
Market Data 
Markets 
